Table 3:
LIS Compared to Non-LIS within Trajectory Group After Propensity Score Weighting
| Consistently High | Slow Decline, Increase Later | Rapid Decline, Increase Later | Slow Decline | Rapid Decline | Consistently Low | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LIS | No LIS | Std Diff | P-Value | LIS | No LIS | Std Diff | P-Value | LIS | No LIS | Std Diff | P-Value | LIS | No LIS | Std Diff | P-Value | LIS | No LIS | Std Diff | P-Value | LIS | No LIS | Std Diff | P-Value | |
| N | 629 | 942 | 93 | 370 | 50 | 291 | 121 | 260 | 24 | 138 | 77 | 349 | ||||||||||||
| Age, Mean(SD) | 74.4 (6.1) | 74.2 (6.0) | 0.02 | 0.65 | 73.6 (6.0) | 73.8 (5.8) | −0.04 | 0.76 | 73.5 (4.9) | 73.7 (5.8) | −0.04 | 0.82 | 74.4 (6.0) | 74.4 (6.0) | −0.01 | 0.94 | 74.7 (5.1) | 74.4 (5.8) | 0.07 | 0.81 | 75.5 (5.9) | 75.0 (6.0) | 0.08 | 0.53 |
| Race | 0.03 | 0.56 | −0.05 | 0.67 | 0.11 | 0.50 | 0.02 | 0.88 | 0.24 | 0.31 | <0.01 | 0.96 | ||||||||||||
| White | 84.2% | 85.3% | N.S.* | 88.4% | N.S.* | 88.1% | 89.0% | 89.5% | N.S.* | 87.9% | N.S.* | 90.5% | ||||||||||||
| Ethnicity | −0.09 | 0.10 | 0.01 | 0.91 | 0.15 | 0.29 | 0.01 | 0.91 | 0.14 | 0.57 | 0.04 | 0.73 | ||||||||||||
| Hispanic | 6.6% | 8.9% | N.S.* | N.S.* | N.S.* | N.S.* | N.S.* | 6.8% | N.S.* | 4.4% | N.S.* | 5.1% | ||||||||||||
| Urbanicity | −0.02 | 0.67 | 0.14 | 0.21 | −0.12 | 0.50 | 0.04 | 0.73 | −0.01 | 0.97 | 0.06 | 0.63 | ||||||||||||
| Metro | 82.8% | 81.9% | 77.6% | 83.2% | N.S.* | 83.0% | 82.5% | 84.0% | N.S.* | 85.2% | 82.6% | 84.9% | ||||||||||||
| Not Metro | 17.2% | 18.1% | 22.4% | 16.8% | N.S.* | 17.0% | 17.5% | 16.0% | N.S.* | 14.8% | 17.4% | 15.1% | ||||||||||||
| Year Diagnosed | 0.05 | 0.37 | 0.04 | 0.76 | −0.01 | 0.93 | 0.01 | 0.91 | 0.06 | 0.82 | 0.03 | 0.83 | ||||||||||||
| 2008 | 67.8% | 69.9% | 69.9% | 71.5% | 67.8% | 67.1% | 64.9% | 65.6% | N.S.* | 57.9% | 67.6% | 68.9% | ||||||||||||
| 2009 | 32.2% | 30.1% | 30.1% | 28.5% | 32.2% | 32.9% | 35.1% | 34.4% | N.S.* | 42.1% | 32.4% | 31.1% | ||||||||||||
| Days Between Diagnosis and Generic Introduction, Mean (SD) | 769.4 (177.4) | 773.9 (179.7) | −0.03 | 0.63 | 740.9 (181.5) | 757.4 (175.2) | −0.09 | 0.42 | 799.3 (159.8) | 765.0 (180.8) | 0.20 | 0.26 | 779.4 (185.1) | 781.0 (190.3) | −0.01 | 0.94 | 747.1 (127.4) | 785.9 (194.6) | −0.24 | 0.43 | 761.2 (161.4) | 771.3 (172.8) | −0.06 | 0.65 |
| Comorbidity | <0.01 | 0.94 | 0.13 | 0.25 | 0.36 | 0.03 | 0.03 | 0.77 | 0.34 | 0.20 | 0.11 | 0.38 | ||||||||||||
| 0 | 49.8% | 50.0% | 61.0% | 54.4% | 41.5% | 59.1% | 46.5% | 48.1% | N.S.* | 57.0% | 44.5% | 50.2% | ||||||||||||
| 1+ | 50.2% | 50.0% | 39.0% | 45.6% | 58.5% | 40.9% | 53.5% | 51.9% | N.S.* | 43.0% | 55.5% | 49.8% | ||||||||||||
| Number of Other Drugs Mean (SD) | 10.1 (6.3) | 10.1 (6.4) | −0.01 | 0.88 | 8.7 (5.1) | 8.8 (5.2) | −0.02 | 0.87 | 9.5 (4.7) | 7.9 (4.8) | 0.33 | 0.057 | 10.1 (6.2) | 9.5 (5.7) | 0.09 | 0.43 | 12.1 (5.4) | 8.9 (5.5) | 0.59 | 0.026 | 10.1 (5.5) | 9.7 (5.4) | 0.09 | 0.51 |
| Exemestene or Lenezotrole | 44.1% | 43.6% | −0.01 | 0.85 | 38.9% | 40.5% | −0.03 | 0.77 | 55.2% | 47.0% | −0.17 | 0.34 | 50.2% | 52.2% | 0.04 | 0.72 | 50.3% | 61.0% | 0.22 | 0.41 | 53.0% | 49.0% | −0.08 | 0.54 |
| Anastrozole | 55.9% | 56.4% | 61.1% | 59.5% | 44.8% | 53.0% | 49.8% | 47.8% | 49.7% | 39.0% | 47.0% | 51.0% | ||||||||||||
Note:
*
N.S.=not stated dues to sample size restrictions. Std. Diff. = standardized difference